Across TCGA pan-cancer cohorts, ABHD17AP6 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ABHD17AP6 data layer compared with 22 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ABHD17AP6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ABHD17AP6 expression acts as an unfavorable survival marker.
LUSC, PRAD, and ESCA are the cancer types where ABHD17AP6 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.